Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900863 | 1.00 | SIGMAR1 (0.36) | SIGMAR1EPHX1TP53KDM4EGMNN | |
| SCHEMBL17337998 | 0.97 | SIGMAR1 (0.34) | SIGMAR1EPHX1TP53KDM4EGMNN | |
| Hydrochloric Acid SCHEMBL7752335 | 0.97 | SIGMAR1 (0.34) | SIGMAR1EPHX1TP53KDM4EGMNN | |
| SCHEMBL28859139 | 0.97 | SIGMAR1 (0.32) | SIGMAR1EPHX1 | |
| Hydrochloric Acid SCHEMBL5405721 | 0.94 | SIGMAR1 (0.31) | SIGMAR1KDM4EGMNNLMNAMAPT | |
| SCHEMBL75236 | 0.85 | — | — | |
| SCHEMBL9580774 | 0.79 | SIGMAR1 (0.38) | SIGMAR1EPHX1TP53LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10714381 | 0.77 | SIGMAR1 (0.37) | SIGMAR1EPHX1KDM4EGMNNLMNA | |
| SCHEMBL2067553 | 0.76 | CYP1A2 (0.37) | SIGMAR1LMNASMN1; SMN2 | |
| SCHEMBL20854885 | 0.76 | LMNA (0.32) | SIGMAR1TP53KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | SIGMAR1 3044/4885EPHX1 222/4885TP53 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.